Telix and ITM Announce Strategic Merger to Enhance Radiopharmaceutical Capabilities

Telix has confirmed a strategic agreement to merge with ITM Isotope Technologies Munich SE, a leader in the production of radioisotopes and radiopharmaceutical development. This merger aligns with Telix’s growth strategy, enhancing its capabilities in development, isotope production, and global manufacturing to deliver innovative treatments to patients worldwide.

ITM is recognized as the leading global supplier of therapeutic radioisotopes, specializing in the production of lutetium-177 (177Lu), actinium-225 (225Ac), and terbium-161 (161Tb). As the sole producer of commercially scalable 177Lu, ITM is a pivotal provider for both available and forthcoming therapeutic radiopharmaceuticals. The company reported an impressive compound annual growth rate (CAGR) of 40% from 2021 to 2025, generating an annual revenue of $273 million in 2025.

The merger, valued at an upfront consideration of $1.65 billion on a cash-free/debt-free basis, includes a share payment of approximately $1.25 billion to ITM shareholders at $11.841 per share, with additional contingent payments possible up to $700 million based on regulatory approvals and commercial sales milestones for ITM-11 (177Lu-edotreotide).

ITM-11, a novel therapeutic candidate for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs), has successfully completed Phase 3 development and could facilitate Telix's entry into a validated market for targeted radionuclide therapy (TRT). The merger is anticipated to create substantial synergy and boost Telix's market position.

Approval from Telix shareholders is required for the transaction, which has already gained support from ITM shareholders representing over 90% of the company’s shares. Following the merger, Telix shareholders are projected to own approximately 76.3%, while ITM shareholders are expected to hold about 23.7% of the combined entity.

The boards of both companies have endorsed the transaction, which is expected to close by the end of FY 2026, pending necessary regulatory approvals and other customary closing conditions. An investor conference call is scheduled to provide further insights into the merger's implications for both companies and shareholders.